Obizur market seen growing through 2030 as hemophilia cases rise

The Obizur market is set for steady growth through 2030, driven by more hemophilia A diagnoses, broader use of personalized therapies and higher healthcare spending. North America held the largest market share in 2025, according to The Business Research Company.

Why it matters: - Obizur is used to treat bleeding episodes in hemophilia A patients who have inhibitors to standard factor VIII therapy. - Rising diagnoses and greater treatment access are expanding demand for rare-disease therapies. - The market outlook points to continued growth through 2030 as healthcare systems invest more in specialized infusion care and biologic treatments.

What happened: - The Business Research Company published its Obizur Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Obizur market is gaining momentum from advances in treatment options and increased awareness of hemophilia A. - The report also highlights North America as the largest regional market in 2025.

The details: - Obizur is the trade name for susoctocog alfa, a recombinant human coagulation factor VIII medication. - The drug is used for bleeding episodes in hemophilia A patients who have developed inhibitors against traditional factor VIII therapies. - Obizur helps restore clotting function in patients with acquired hemophilia A. - Historical growth came from recombinant factor VIII breakthroughs, better diagnosis of acquired hemophilia A, more specialized hematology centers, wider access to hospital infusion therapy and greater awareness of bleeding risks tied to inhibitors. - Forecast growth is expected to come from broader adoption of personalized hemophilia treatments, more home-based infusion capability, higher investment in rare-disease therapies, stronger inhibitor management and continued innovation in recombinant biologics. - Key trends in the forecast period include more use of recombinant coagulation factors, more emphasis on inhibitor-tolerant hemophilia therapies, expansion of hospital specialty infusion services, higher demand for rapid bleeding control solutions and better cold-chain logistics and storage. - The report includes Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report offers a free sample at the sample request page. - The full report is available here.

Between the lines: - The market thesis is tied less to one drug and more to a broader shift in hemophilia care toward individualized treatment and faster bleed control. - The report’s emphasis on hospital infusion services and cold-chain logistics suggests distribution and care delivery remain important constraints, not just drug development. - The healthcare spending data points to a favorable funding backdrop for specialty and rare-disease medicines. - A UK government report cited in the release said total healthcare expenditure rose 5.6% nominally from 2022 to 2023, after 0.9% growth in the prior year. - The National Institutes of Health in the UK recorded 6,662 males diagnosed with hemophilia A between April 2022 and March 2023.

What's next: - The report expects demand to keep rising as more patients are diagnosed and treated for bleeding episodes linked to factor VIII deficiency or inhibitors. - Growth will likely track investment in rare-disease care, home infusion capability and newer recombinant therapies. - Regional competition could widen as Asia-Pacific and other markets expand access to specialized hemophilia treatment.